Trial reportRheumatology (Oxford, England)2026
Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active PsA: data from the GOLMePsA clinical trial.
Trial report in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04108468 (An Investigator-initiated Double-blind, Parallel-group Randomised Controlled Trial of GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA Using Clinical and Whole Body MRI Outcomes), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Investigator-initiated Double-blind, Parallel-group Randomised Controlled Trial of GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA Using Clinical and Whole Body MRI Outcomes: the GOLMePsA Study.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo describe the prevalence and extent of whole body (WB)-MRI detected joint disease features and their response to therapy in patients with early, active PsA.
methodsNewly diagnosed PsA patients (treatment-naïve), recruited in the GOLMePsA randomized trial (MTX plus golimumab and steroids, GOLMTX vs MTX plus steroids, PBOMTX), underwent a multi-joint MRI protocol (baseline; week 24 [primary outcome] and week 36). The validated WIPE (peripheral joints and entheses); HIMRISS, KIMRISS (hip and knee); HEMRIS (heel) and CANDEN and SPARCC (sacroiliac joints (SIJs), spine) scores were recorded. Exploratory estimates of difference or ratios (with CIs; 75-95%) between groups at weeks 24 and 36 were obtained using multiple binary logistic or quantile (median) regression.
resultsOverall, 93 paired scans from 31 participants (median symptom duration 10.5 months; IQR 4.2-18.3; absolute range 1.8-197.7; 68% polyarticular) were included. Baseline scores showed widespread low intensity inflammation in peripheral tissues (median MRI-WIPE score: 37-CI 19.0-55.0). SIJs and spine inflammation (SPARCC score ≥2) was seen in 25.8% (10/31) and 32.3% (10/31), respectively. Participants achieved median MRI-WIPE delta (the difference between time points) of -10 at week 24 and -7 at week 36 in the GOLMTX and -6 and -9 in PBOMTX arms, respectively. No differences between the treatment groups were observed.
conclusionsIn this exploratory analysis, WB-MRI identified widespread although low intensity inflammation in peripheral joints and enthesis with improvements seen at 24 and 36 weeks and no meaningful differences between treatment arms. Axial abnormalities were seen in one third of patients at baseline. CLINICAL
trial registrationClinicaltrials.gov; NCT04108468.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.